ArticleIranian journal of child neurology2026
Cost-Effectiveness and Cost-Utility Analysis of Cinnarizine Compared to Valproate in Pediatric Migraine: An Iranian Perspective.
Article in Iranian journal of child neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Childhood migraine is a prevalent neurovascular disease in children with a considerable reduction in quality of life and high social cost. Anticonvulsants, such as Valproate and calcium channel blockers, including Cinnarizine are used frequently as preventive medications. This research evaluates the cost-effectiveness and cost-utility of Cinnarizine versus Valproate in managing childhood migraine, based on an Iranian societal perspective. Materials & Methods: A randomized cohort trial was conducted, involving 150 children aged 5 to 17 years at the Imam Reza Clinic in Shiraz, Iran. Patients were administered Cinnarizine (1-2 mg/kg/day) or Valproate (10-20 mg/kg/day) for three months, evaluated by decision-tree models for cost-utility and cost-effectiveness. Effectiveness was measured by reduction in migraine attack frequency and Quality-Adjusted Life Years (QALYs). Costs were obtained from patient medical records, questionnaires, and national datasets, including direct and indirect costs. Sensitivity analysis, such as Monte Carlo simulations, was performed to validate the results. Results: Patients receiving Cinnarizine experienced a mean QALYs of 0.213 versus 0.209 for the Valproate group and a higher rate of response at 26% (Cinnarizine) versus 14% (Valproate). Total costs during the study period favored Cinnarizine ($183 vs. $191) with an Incremental Cost Effectiveness Ratio of $-156 per additional effect and an Incremental Cost Utility Ratio of $-2069 per QALYs. Adverse effects noted were drowsiness (17.8%) for the Cinnarizine and dizziness (13.5%) for the Valproate arm. Probabilistic sensitivity analysis contained an 88.2% probability that Cinnarizine was cost-effective with a willingness-to-pay of $17,922 per QALYs. Conclusion: Cinnarizine was a cheaper option compared to Valproate as a prophylactic agent in pediatric migraine in Iran with higher response rates, lower expenses, and similar effectiveness. Further research with long-term follow-ups and varied populations is needed to validate the results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.